Chi-Med
AIM: £43.10 (+0) | Nasdaq: $29.35 (+0.35)
Search
About Us
Innovation Platform
Overview
Our Pipeline
R&D Approach
Key Corporate Partnerships
Innovation News
Commercial Platform
Overview
Prescription Drugs
Competitive Advantages
Main Products
Consumer Health
Commercial Platform News
News & Presentations
Recent News
All RNS & Press Releases
Presentations & Publications
Leadership & Governance
Our Leadership
Board of Directors
Senior Management
Corporate Information
Terms of Reference & Policies
Financial Results
Overview
Financial Highlights
Chairman's Statement
Financial Reports
SEC Filings
Shareholder Information
Overview
Share Price & Chart
Major Shareholders
Events, Circulars & Forms
Analyst Coverage
Dual-listing FAQs
Information for Shareholders
Warning to Shareholders
AIM Rule 26
About Us
Innovation Platform
Overview
Our Pipeline
R&D Approach
Key Corporate Partnerships
Innovation News
Commercial Platform
Overview
Prescription Drugs
Competitive Advantages
Main Products
Consumer Health
Commercial Platform News
News & Presentations
Recent News
All RNS & Press Releases
Presentations & Publications
Leadership & Governance
Our Leadership
Board of Directors
Senior Management
Corporate Information
Terms of Reference & Policies
Financial Results
Overview
Financial Highlights
Chairman's Statement
Financial Reports
SEC Filings
Shareholder Information
Overview
Share Price & Chart
Major Shareholders
Events, Circulars & Forms
Analyst Coverage
Dual-listing FAQs
Information for Shareholders
Warning to Shareholders
AIM Rule 26
FY2018 Results & Programs Update
Announcement and Presentation webcast
View Event Details
Fruquintinib Approved
CEO Christian Hogg on CNBC Squawk Box
Watch Interview Excerpt
Fruquintinib in JAMA
Full text of FRESCO colorectal cancer trial published
Read Abstract
Royal Society of Medicine
CEO Christian Hogg speaks at
RSM Medical Innovations Summit
Watch Presentation
AstraZeneca & Chi-Med
Harnessing the power of Chinese scientific innovation
Learn More
Latest News
Group
|
21 Mar 2019
2018 Annual Report and Notice of Annual General Meeting
Group
|
11 Mar 2019
Publication of Form 20-F
Group
|
11 Mar 2019
Chi-Med Reports 2018 Full Year Results and Provides Updates on Key Clinical Programs
Innovation Platform
|
12 Feb 2019
Chi-Med Highlights Preliminary Phase II Savolitinib / Imfinzi® Combination Data in Advanced Papillary Renal Cell Carcinoma at 2019 ASCO Genitourinary Cancers Symposium
Group
|
8 Feb 2019
Chi-Med to Announce 2018 Final Results
Current Share Price
London AIM:HCM
£43.10
+0 | 21-Mar-2019 | 08:00 BST
Nasdaq:HCM
US$29.35
+0.35 | 20-Mar-2019 | 16:00 EST
Note: 1 Nasdaq share = ½ AIM share
Latest Presentations
11 Mar 2019
2018 Full Year Results
4 Mar 2019
Clin Cancer Res: Surufatinib in advanced, well-differentiated neuroendocrine tumors
7 Jan 2019
37th Annual J.P. Morgan Healthcare Conference
27 Jul 2018
2018 Half-Year Financial Results
Latest Reports
Annual Report 2018 (with Form 20-F)
EN
Interim Report 2018
EN
Annual Report 2017 (with Form 20-F)
EN
Share conversions between AIM & Nasdaq
Mailing list sign-up
Analyst Coverage
Bank of America Merrill Lynch
Canaccord Genuity
Deutsche Bank
Edison
Panmure Gordon
Trinity Delta
The leading China-based innovator
Our
Innovation Platform
focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases.
Learn More
A powerful commercial network in China
Our
Commercial Platform
manufactures, markets and distributes prescription and over-the-counter pharmaceuticals in China.
Learn More